Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2025-03-27 M&A Activity
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the finalization of a tangible asset acquisition (real estate) by SCM Lifescience Co., Ltd. Since this document reports the completion of a specific corporate transaction (asset acquisition) rather than a general regulatory announcement or a report publication notice, and it does not fit into specific categories like M&A (which usually refers to corporate mergers/takeovers) or capital changes, it falls under the 'Regulatory Filings' category as a formal disclosure of a completed material event.
2025-03-27 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by SCM Lifescience. It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2025-03-24 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from SCM Lifescience Co., Ltd. regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the issuance of new shares, the third-party allocation method, the purpose of the funds, and the specific details of the entities involved in the capital increase. This type of filing is a direct announcement of a capital structure change and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-03-24 Korean
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from a Korean company (SCM Lifescience) announcing a change in its largest shareholder due to a third-party capital increase. This type of disclosure is a standard regulatory requirement for publicly traded companies to inform the market of significant changes in ownership structure and control. It does not fit into specific categories like 'Director's Dealing' (which is for individual insider trades) or 'Major Shareholding Notification' (which is typically filed by the investor). Therefore, it is classified as a general regulatory filing.
2025-03-24 Korean
기타시장안내(최대주주의의무보유관련)
Major Shareholding Notification Classification · 100% confidence The document is a regulatory notice issued by the Korea Exchange (KRX) regarding SCM Lifescience. It informs the market about the mandatory holding period (lock-up) requirements for the company's largest shareholder following a change in control and a third-party capital increase. Since this is a regulatory announcement regarding market rules and compliance rather than a financial report, dividend notice, or management change, it falls under the general regulatory filing category.
2025-03-24 Korean
주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for SCM Lifescience, detailing the date, location, and agenda items (amendment of articles of incorporation and appointment of directors). This type of document is a precursor to the meeting itself, intended to inform shareholders of the upcoming vote, which falls under the category of Proxy Solicitation & Information Statement (PSI).
2025-03-24 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.